Achiko

  • About
  • Products
    • Aptamex
    • Teman Sehat
  • Team
  • News
  • Investor
    • Announcements
    • Research
    • Financials
  • Contact
  • English

Achiko AG Production and Sales Update

21 December 2022

  • AptameX™ Gen 2 Covid-19 rapid calibration outperforms Abbott Pan Bio and Clugene’s rapid tests in Indonesia in validation tests.
  • Sample of 20 PCR Positive and 9 Negative samples, indicated a 100% match between AptameX™ Gen 2 product to PCR, whilst Clungene and Abbott’s Pan Bio were between 6% and 50% sensitive only.
  • Achiko remains committed to sales and is resolving production issues.

Zurich, 21 December 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to provide updates on test performance, production and sales.

Test Performance

As the Company is proceeding to sales and is currently going through external validation, the Company is proud to report that early results indicate a strong performance against other forms of testing (see table below).

PCRAbbott
Rapid Antigen
Nasal Swab
Clungene
Rapid Antigen
Nasal Swab
Clungene
Rapid Antigen
Saliva
AptameX
Rapid Aptamer
Saliva
Sensitivity100%50%38%6%100%
Specificity100%100%100%100%100%
n=29, mean CT 25.88

“The price versus performance, user friendliness, and the affordability of the test compares well against other categories of testing,” said Steven Goh, CEO of Achiko AG.  “As the world considers Covid-19 as endemic, the shift is now to deliver the right test for key industries such as healthcare, manufacturing, tourism and leisure, key government and other applications.”

“Additionally, these results pave the way for other tests.  The diagnostic industry responded quickly with PCR and rapid testing, and our success with AptameX™ opens up a new field of more accessible and precise diagnostics.”

Unlike molecular and immunoassay approaches, the test’s use of DNA aptamers has yielded encouraging results at low viral loads outperforming most lateral flow based rapid tests. This is particularly important as early detection provides communities the opportunity to better manage and minimise the spread of the virus, treat the affected population more effectively, and limit adverse effects on economies and people’s livelihood.

Production and Sales

Earlier in 2022, the Company signed a Sales and Marketing agreement with Nahdlatul Ulama (DKI), with the view of supplying over 5 million tests per month.  The Company has secured plastic moulding and supply to respond to that demand, but has been slowed by corporate distractions and production issues as it upgraded from the initial Gen 1 product to an even more precise Gen 2 product for scale production.

“The support from our Swiss investors in September, and the Annual General Meeting has paved the way for the Company to update and strengthen its board with a blend of local and international experience and reorganise its balance sheet,” added Goh.  “Sales and securing raw materials aren’t the problem, it’s been organsing production.  This is the first time that anyone has produced a non-invasive, highly sensitive and specific aptamer-based solution that can potentially transform accessibility and affordability in a range of markets for a range of applications. Understandably, that’s not without challenges and, whilst we’ve made significant progress, it’s taken longer than expected to understand and address the issues to be ready for commercial launch and scaling and accordingly, we are still not producing the levels planned. However, we believe we understand the issues now and are moving quickly to resolve the situation.” The Company is grateful for the support of its partners on the ground who have been instrumental in helping prepare for this and are excited by the opportunity to introduce more accessible and precise diagnostics to the population at large.  There has been no change in the levels of demand for AptameX and the Company is expecting to supply in volume in accordance with previous indications.

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport.  AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.  

The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.  

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:  

ACHIKO AG

Investor Relations
E: ir@achiko.com

Switzerland & Global

Marcus Balogh
Farner Consulting Ltd
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer 

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. In consequence, no undue reliance should be placed on these forward-looking statements by investors. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Filed Under: Ad-hoc Announcements, Announcement

Achiko AG issues a convocation notice to its shareholders for its Annual General Meeting on 20 December 2022

25 November 2022

Zurich, 25 November 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB:  ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) has issued a convocation notice to its shareholders for the Company’s Annual General Meeting taking place at 10:00 a.m. (CET) on 20 December 2022, in the offices of the Notary public Notariat Riesbach-Zurich, Kreuzstrasse 42, 8008 Zurich Zurich.

Due to the Covid-19 pandemic, this year’s Annual General Meeting will be held in accordance with art. 27 para. 1 letter b of the Covid-19-Ordinance 3 without physical presence of the shareholders. Shareholders may exercise their shareholders’ rights through the independent proxy only, as further set out in the invitation to the Annual General Meeting. The Board of Directors regrets not being able to welcome the shareholders to the Annual General Meeting this year and requests shareholders to make use of their ability to participate through the independent proxy.

Only shareholders that are registered with their personal information in the Company’s shareholder ledger may participate in the Annual General Meeting. Unregistered shareholders who wish to participate in the Annual General Meeting are kindly requested to contact the financial institution that holds the respective shares and to request their registration. The cut-off date for the participation in the Annual General Meeting is 5 December 2022. Only shareholders entered in the shareholder ledger with the right to vote until 5 December 2022 will be entitled to participate in the Annual General Meeting. For technical and legal reasons, shares cannot be registered directly through Achiko AG. Note that during the period from 5 December 2022 until and including 20 December 2022, no entries of shares will be made in the shareholder ledger.

The invitation to the Annual General Meeting of Achiko, containing the full agenda, the proposals of the Board of Directors as well as further information, is available as of today at https://www.achiko.com/financials.

ABOUT ACHIKO AG 

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport.  AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.  

The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.  

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world. 

Media contacts:  

ACHIKO AG

Investor Relations
E: ir@achiko.com

Switzerland & Global

Marcus Balogh
Farner Consulting Ltd
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer 

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. In consequence, no undue reliance should be placed on these forward-looking statements by investors. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise

Filed Under: Ad-hoc Announcements, Announcement

Achiko AG Commences Commercial Deliveries in Indonesia

14 November 2022

  • Commencing Commercial Deliveries of its Generation 2 AptameXTM Covid-19 tests kits with Nahdlatul Ulama DKI in Jakarta, Indonesia

Zurich, 14 November 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB:  ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) is proud to announce that following pilot production with manufacturing partner PT Indofarma Tbk, the Company is now commencing commercial deliveries of its Generation 2 AptameX™ Covid-19 test kit to Nahdlatul Ulama DKI (NU) and other commercial clients, both starting in and around Jakarta.

“We’re excited to commence commercial deliveries in Indonesia.  Following a pilot program in Jakarta earlier this year we will resume the rollout of AptameX to schools and businesses,” stated Steven Goh, CEO of Achiko.  “As the world moves to treating Covid-19 as endemic, AptameX represents the right combination of a friendly, affordable and accurate solution for the future.”

Nahdlatul Ulama DKI is the Jakarta branch of Nahdlatul Ulama, which nationally in Indonesia has over 90 million registered members and operates over 6,000 schools and universities, and several hundred hospitals and clinics.  Achiko had earlier in 2022 signed a marketing and sales agreement to deliver 1 million tests, before growing to 5 million per month in 2022.

AptameX is a saliva based Covid-19 test using DNA aptamers bound to gold nanoparticles in a colloidal solution, and the result is read by a UV Spectrophotometer and then analysed with custom software.  Unlike molecular and immunoassay approaches, the test’s use of DNA aptamers has yielded encouraging results at low viral loads outperforming most lateral flow based rapid tests.

“We’ve had some distractions along the way, but we’re excited to get things back on track.  We’ve secured materials supply, and establishing production in Indonesia and Taiwan, and now we’re looking forward to delivering on a solution that’s right for Indonesia and bringing it to the world,” added Goh.

ABOUT ACHIKO AG 

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport.  AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.  

The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.  

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world. 

Media contacts:  

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Filed Under: Ad-hoc Announcements, Announcement

Achiko AG Production and Company Update

2 November 2022

  • Completing Production Pilot for Generation 2 of AptameXTM as a Precursor to Mass Commercial Production
  • Expect to Commence Delivery to Sales and Marketing Contract with Nahdlatul Ulama on Commencement of Mass Production

Zurich, 2 November 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB:  ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) is proud to announce that it has successfully completed a production test with PT Indofarma Tbk as a precursor to mass production of its Generation 2 AptameX™ Covid-19 test kit.  Generation 1 was successfully calibrated and delivered near perfect results earlier this year.  Generation 2 is optimised for cost and production.

“We’re excited to pass this milestone”, said Mr Steven Goh, CEO of Achiko AG. “We’ve been distracted with corporate issues this year, and we’re keen to get back to delivering on our sales and marketing contract with Nahdlatul Ulama.”

Earlier in 2022, the Company announced a sales and marketing contract with Nahdlatul Ulama, the world’s largest Islamic organisation with over 90 million registered members primarily in Indonesia.   The plan was to deliver 5 million tests per month in Q4 2022 rising to over 10 million per month in 2023.  The contract is currently behind, however the Company expects to commence delivery as the Company enters the new year.

“As we move to the endemic phase, Covid-19 presents a serious challenge for healthcare, critical manufacturing, key services such as government and education, tourism, and leisure.  The distractions in the middle of the year are regrettable and we are working with key shareholders and partners to organise ourselves with the right board and management configuration to more consistently realise the value of an affordable, fast, highly accurate, user friendly Covid-19 test such as AptameX in low and middle income countries (LMIC) such as Indonesia,” added Goh.

ABOUT ACHIKO AG 

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport.  AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.  

The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.  

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world. 

Media contacts:  

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Filed Under: Ad-hoc Announcements, Announcement

Achiko AG Appoints New Chief Financial Officer

7 October 2022

Zurich, 7 October 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB:  ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) a healthcare technology company that is developing new innovations and disruptive diagnostic solutions that put people first announced that it has appointed Lars Birkmann as Chief Financial Officer (CFO) as of 5th October 2022, succeeding Adam O’Keeffe as ad interim CFO.

Mr Birkmann, 44, has successfully worked in the Swiss life sciences sector for over twenty years and has been involved in all areas of finance from accounting, financial control, treasury, and mergers and acquisitions.  He will take over the CFO position at Achiko and join the Company’s Executive Committee.  Prior to Achiko, Lars was the CFO at Ender Diagnostics AG (Bern) and before that the CFO for Sensile Medical AG (Olten). 

Lars has completed his studies in Economics and Study in Law, and a degree in Business from the Business School in Leipzig. He is also a federal expert in European and Swiss VAT law.

“We are excited to welcome Lars on board”, said Mr Steven Goh, CEO of Achiko AG.  “It’s the start of a process to build an executive team and Board with Swiss representation and is a decisive step towards the Company’s final transformation into becoming a diagnostics and technology company.”

ABOUT ACHIKO AG 

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport.  AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.  

The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.  

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world. 

Media contacts:  

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Filed Under: Ad-hoc Announcements, Announcement

  • 1
  • 2
  • 3
  • …
  • 8
Achiko
  • Facebook
  • Instagram
  • Twitter
  • Linkedin
  • Youtube
Copyright © Achiko AG 2023
Legal
  • Privacy Policy
  • Terms and Conditions
Quick Link
  • About
  • AptameX
  • Teman Sehat
  • News
  • Investor
  • Contact
  • English